检索结果-南通市图书馆

One more chance of fistula healing in inflammatory bowel disease:Stem cell therapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2018年第12期6卷 493-500页

作者： Erica P Turse francis E dailey Maliha Naseer Edward K Partyka Veysel Tahan Division of Gastroenterology and Hepatology Department of Internal MedicineUniversity of Missouri Health Center

Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including anti-biotics, immunomodulators, anti-tumor necrosis factor--α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%--88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi--approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.

关键词： Crohn’s disease Stem cells Mesenchymal Fistulizing Fistula Inflammatory bowel disease

Interventions to improve sarcopenia in cirrhosis: A systematic review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2019年第2期7卷 156-170页

作者： Maliha Naseer Erica P Turse Ali Syed francis E dailey Mallak Zatreh Veysel Tahan Department of Internal Medicine Division of Gastroenterology and Hepatology East Carolina University Department of Internal Medicine Division of Gastroenterology St Joseph Hospital Medical Center/Creighton University Department of Internal Medicine University of Missouri Department of Internal Medicine Division of Gastroenterology and Hepatology University of Missouri

BACKGROUND Sarcopenia, i.e., muscle loss is now a well-recognized complication of cirrhosis and in cases of non-alcoholic fatty liver disease can contribute to accelerate liver fibrosis leading to cirrhosis. Hence, it is imperative to study interventions which targets to improve sarcopenia in *** To examine the relationship between interventions such nutritional supplementation, exercise, combined life style intervention, testosterone replacement and trans jugular intrahepatic portosystemic shunt(TIPS) to improve muscle mass in *** We search PubMed, EMBASE and Cochrane between June-August 2018, without a limiting period and the types of articles(RCTs, clinical trial, comparative study)in adult patients with sarcopenia and cirrhosis. The primary outcome of interest was improvement in muscle mass, strength and physical function interventions mentioned above. In the screening process, 154 full text articles were included in the review and 129 studies were *** We identified 24 studies that met review inclusion criteria. The studies were diverse in terms of the design, setting, interventions, and outcome *** performed only qualitative synthesis of evidence due to heterogeneity amongst studies. Risk of bias was medium in most of the included studies and low quality of evidence showed improvement in the muscle mass, strength and physical function following aerobic exercise. 60% of the included studies on the nutritional intervention, 100% of the studies on testosterone replacement in hypogonadal men and trans-jugular portosystemic shunt were proved to be effective in improving sarcopenia in *** Although the quality of evidence is low, the findings of our systematic review suggest improvement in the sarcopenia in cirrhosis with exercise, nutritional interventions, hormonal and TIPS interventions. High quality randomized controlled trials needed to further strengthen these findings.

关键词： Sarcopenia Cirrhosis Treatment Intervention Nutrition Therapy Exercise Testosterone Trans jugular intrahepatic portosystemic shunt

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatoma Research 2017年第12期3卷 302-308页

作者： Walid SAyoub francis dailey Paul Martin Patricia DJones Department of Gastroenterology and Hepatology Cedars Sinai Medical CenterLos AngelesCA90048USA David Geffen School of Medicine University of California Los AngelesLos AngelesCA90095USA Division of Hepatology Department of MedicineUniversity of Miami Miller School of MedicineUniversity of MiamiMiamiFL33136USA Sylvester Comprehensive Cancer Center University of MiamiMiamiFL33136USA.

Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women;HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of which occur in China - and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of the deaths from HCC are associated with hepatitis B virus (HBV). Fortunately, HBV vaccination and antiviral therapy have shown excellent efficacy in decreasing the incidence of HCC. We will discuss the relationship of HBV to HCC, address available treatments for HBV and the impact of treatment on the development of HCC.

关键词： Liver cancer hepatocellular carcinoma hepatitis B nucleos(t)ides entecavir tenofovir lamivudine

Implications of COVID-19 for inflammatory bowel disease:Opportunities and challenges amidst the pandemic

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Meta-Analysis 2020年第5期8卷 383-399页

作者： Maliha Naseer Shiva Poola francis E dailey Hakan Akin Veysel Tahan Division of Gastroenterology and Hepatology Department of Internal MedicineEast Carolina UniversityGreenvilleNC 27834United States Department of Internal Medicine/Pediatrics Brody School of Medicine/Vidant Medical CenterGreenvilleNC 27834United States Division of Gastroenterology and Hepatology Department of Internal MedicineUniversity of MissouriColumbiaMO 65212United States

Since the beginning of the coronavirus disease 2019(COVID-19)pandemic various measures have been taken to mitigate the effects of the global health crisis in this unprecedented *** to the World Health Organization,more than 5 million people have been infected with severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)and with more than 300000 deaths attributed to COVID-19 *** is emerging evidence that SARS-CoV-2 utilizes angiotensin-converting enzyme 2 receptors to enter human cells which are found in abundance in the alveoli and *** addition,the infection is noted to be more severe in patients with co-morbid conditions,those who are malnourished,immunosuppressed and *** bowel disease(IBD)which includes ulcerative colitis and Crohn’s disease is chronic remitting and relapsing disorders with intestinal and extraintestinal *** patients are often malnourished and on immunosuppressive medications and there is a hypothetical concern that IBD patients are at substantial risk of COVID-19 *** management of IBD patients is often complex and poses unique challenges for gastroenterologists during the *** purpose of this review article is to summarize the growing level of evidence and understanding of the management of IBD during the COVID-19 pandemic,in the light of international and national gastroenterology society *** performed a thorough literature search on IBD,SARS-CoV-2 and COVID-19 on PubMed,EMBASE,OVID Medline and Google Scholar and pertaining literature was critically examined and *** national and international society guidelines and recommendations,IBD is not a risk factor for SARS-CoV-2 *** patients should continue with their medications and they should follow universal precautions ***,hand and respiratory hygiene and avoidance of health care facilities and public toilets as general *** IBD patients older age,having act

关键词： SARS-CoV-2 COVID-19 Inflammatory bowel disease Crohn’s disease Ulcerative colitis Pandemic

Review of stem cells as promising therapy for perianal disease in inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Transplantation 2018年第4期8卷 97-101页

作者： francis E dailey Erica P Turse Maliha Naseer Jack D Bragg Veysel Tahan Division of Gastroenterology and Hepatology Department of Internal Medicine University of Missouri Health Center Division of Gastroenterology and Hepatology Department of Internal Medicine University of Missouri-Columbia

Those patients with perianal Crohn's disease or ul-cerative colitis experience a difficult to treat disease process with a delayed state and often inability to heal despite current therapies. The approaches currently used to treat these patients with corticosteroids,antibiotics,immunomodulators, anti-tumor necrosis factor-α drug, and surgical repair are limited in their healing ability. This review presents all current literature since emergence in the early 2000s of stem cell therapy for patients with perianal inflammatory bowel disease and analyzes the efficacy, outcomes and safety within these studies.

关键词： Crohn’s disease Stem cells Mesenchymal Perianal disease Fistula Inflammatory bowel disease